Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer

British Journal of Cancer

Volumn 92, Issue 9, 2005, Pages 1737-1745

  Yagi, H ^a   Miyamoto, S ^a   Tanaka, Y ^a   Sonoda, K ^a   Kobayashi, H ^a   Kishikawa, T ^b   Iwamoto, R ^c   Mekada, E ^c   Nakano, H ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

EGFR; HB EGF; Ovarian cancer; Peritoneal fluid

Indexed keywords

AMPHIREGULIN; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IODINE 125; LIGAND; LYSOPHOSPHATIDIC ACID; THYMIDINE; TRANSFORMING GROWTH FACTOR ALPHA; TRITIUM;

ADULT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; OVARY CANCER; PERITONEAL FLUID LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ASCITIC FLUID; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 19944391895     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602536     Document Type: Article

References (28)

1. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Aberbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302
2. D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR, Iaffaioli VR, Salomon DS, Normanno N (2002) Transforming growth factor alpha, AR and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol 21: 941-948
3. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB (2000) Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 6: 2482-2491
4. Fischer OM, Hart S, Gschwind A, Ullrich A (2003) EGFR signal transactivation in cancer cells. Biochem Soc Trans 31: 1203-1208
5. Goetzl EJ, Kong Y, Kenney JS (1999) Lysophospholipid enhancement of human T cell sensitivity to diphtheria toxin by increased expression of heparin-binding epidermal growth factor. Proc Assoc Am Physicians 111: 259-269
6. Gschwind A, Hart S, Fischer OM, Ullrich A (2003) TACE cleavage of proAR regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 22: 2411-2421
7. Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M, Mekada E (1994) Heparin-binding EGF-like growth factor, which acts as the diphteria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphteria toxin sensitivity. EMBO J 13: 2322-2330
8. Iwamoto R, Mekada E (2000) Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev 11: 335-344
9. Jayne DG, Perry SL, Morrison E, Farmery SM, Guillon PJ (2000) Activated mesothelial cells produce heparin-binding growth factors: implications for tumor metastases. Br J Cancer 82: 1233-1238
10. Mills GB, May C, McGill M, Roifman CM, Mellers A (1998) A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 48: 1066-1071
11. Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591
12. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E (2004) Heparin-binding EGF-like growth factor and the LPA-induced ectodomain shedding pathway is a promising target for the therapy of ovarian cancer. Cancer Res 64: 5720-5727
13. Morimoto H, Safrit JT, Bonavida J (1991) Synergistic effect of tumor necrosis factor-alpha- and diphteria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol 147: 2609-2616
14. Morishige K, Kurachi H, Amemiya K, Fujita Y, Yamamoto T, Miyake A (1991) Evidence for the involvement of transforming growth factor α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 51: 5322-5328
15. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21
16. Penson RT, Shannon KE, Sharpless NE, Seiden MV (1998) Ovarian cancer an update on genetics and therpapy. Compr Ther 24: 477-487
17. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888
18. Raab G, Klagsbrun M (1997) Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1333: F179-F199
19. Salomon DS, Brandt R, Ciardiello F, Normanno M (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232
20. Scambia G, Benedetti Panci P, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, De Vincenzo R, Mancuso S (1992) Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 10: 529-535
21. Strachan L, Murison JG, Prestidge RL, Sleeman MA, Watson JD, Rumble KD (2001) Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem 25: 18265-18271
22. Tan MS, Tsai JC, Lee YJ, Chen HC, Shin SJ, Lai YH, Parrella MA, Bianchi C, Higashiyama S, Endege W, Lee ME, Tsai JH (1994) Induction of heparin-binding epidermal growth factor-like growth factor mRNA by protein kinase C activators. Kidney Int 46: 690-695
23. Umata T, Hirata M, Takahashi T, Ryu F, Shida S, Takahashi Y, Tsuneoka M, Miura Y, Masuda M, Horiguchi Y, Mekada E (2001) A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 276: 30475-30482
24. Westermann AM, Beijnen JH, Moolenaar WH, Rodenhuis S (1997) Growth factors in human ovarian cancer. Cancer Treat Rev 23: 113-131
25. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S (1998) Malignant effusion contain; lysophosphatidic acid (LPA)-like activity. Ann Oncol 9: 437-442
26. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, Xu Y (2001) Electrospray lonization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290: 302-313
27. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, Holub BJ, Mills GB (1995) Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1: 1223- 1232
28. Yeo EJ, Exton JH (1995) Stimulation of phospholipase D by epidermal growth factor requires protein kinase C activation in Swiss 3T3 cells. J Biol Chem 270: 3980-3988